Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

September 16, 2022

Study Completion Date

September 16, 2022

Conditions
Huntington Disease
Interventions
DIETARY_SUPPLEMENT

Melatonin

Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.

OTHER

Placebo

Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

Huntington's Disease Society of America

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER

NCT04421339 - Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study | Biotech Hunter | Biotech Hunter